Advertisement

Association of Prescription Drug Monitoring Program Use With Opioid Prescribing and Health Outcomes: A Comparison of Program Users and Nonusers

Published:October 17, 2017DOI:https://doi.org/10.1016/j.jpain.2017.10.001

      Highlights

      • We asked if a prescription drug monitoring program (PDMP) changed opioid risks.
      • We matched early PDMP registrants with similarly prescribing nonregistrants.
      • Prescribing risk generally decreased among registrants as well as nonregistrants.
      • Frequent PDMP users showed trends similar to infrequent users.
      • Factors other than PDMP appeared to have greater influence on prescribing trends.

      Abstract

      Prescription drug monitoring programs (PDMPs) are a response to the prescription opioid epidemic, but their effects on prescribing and health outcomes remain unclear, with conflicting reports. We sought to determine if prescriber use of Oregon's PDMP led to fewer high-risk opioid prescriptions or overdose events. We conducted a retrospective cohort study from October 2011 through October 2014, using statewide PDMP data, hospitalization registry, and vital records. Early PDMP registrants (n = 927) were matched with clinicians who never registered during the study period, using baseline prescribing metrics in a propensity score. Generalized estimating equations were used to examine prescribing trends after PDMP registration, using 2-month intervals. We found a statewide decline in measures of per capita opioid prescribing. However, compared with nonregistrants, PDMP registrants did not subsequently have significantly fewer patients receiving high-dose prescriptions, overlapping opioid and benzodiazepine prescriptions, inappropriate prescriptions, prescriptions from multiple prescribers, or overdose events. At baseline, frequent PDMP users wrote fewer high-risk opioid prescriptions than infrequent users; this persisted during follow-up with few significant group differences in trend. Thus, although opioid prescribing declined statewide after implementing the PDMP, registrants did not show greater declines than nonregistrants.

      Perspective

      Factors other than PDMP use may have had greater influence on prescribing trends. Refinements in the PDMP program and related policies may be necessary to increase PDMP effects.

      Key words

      To read this article in full you will need to make a payment
      Subscribe to The Journal of Pain
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Austin P.C.
        A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003.
        Stat Med. 2008; 27: 2037-2049
        • Bao Y.
        • Pan Y.
        • Taylor A.
        • Radakrishnan S.
        • Luo F.
        • Pincus H.A.
        • Shackman B.R.
        Prescription drug monitoring programs are associated with sustained reductions in opioid prescribing by physicians.
        Health Aff (Millwood). 2016; 35: 1045-1051
        • Beil H.
        • Preisser J.S.
        • Rozier R.G.
        Accuracy of record linkage software in merging dental administrative data sets.
        J Public Health Dent. 2013; 73: 89-93
        • Brady J.E.
        • Wunsch H.
        • DiMaggio C.
        • Lang B.H.
        • Giglio J.
        • Li G.
        Prescription drug monitoring and dispensing of prescription opioids.
        Public Health Rep. 2014; 129: 139-147
        • Campbell K.M.
        • Deck D.
        • Krupski A.
        Record linkage software in the public domain: a comparison of Link Plus, The Link King, and a ‘basic’ deterministic algorithm.
        Health Informatics J. 2008; 14: 5-15
        • Chang H.Y.
        • Lyapustina T.
        • Rutkow L.
        • Daubresse M.
        • Richey M.
        • Faul M.
        • Stuart E.A.
        • Alexander G.C.
        Impact of prescription drug monitoring programs and pill mill laws on high-risk opioid prescribers: A comparative interrupted time series analysis.
        Drug Alcohol Depend. 2016; 165: 1-8
        • Deyo R.A.
        • Hallvik S.E.
        • Hildebran C.
        • Marino M.
        • Dexter E.
        • Irvine J.M.
        • O'Kane N.
        • Van Otterloo J.
        • Wright D.A.
        • Leichtling G.
        • Millet L.M.
        Association between initial opioid prescribing patterns and subsequent long-term use among opioid-naïve patients: A statewide retrospective cohort study.
        J Gen Intern Med. 2017; 32: 21-27
        • Deyo R.A.
        • Irvine J.M.
        • Hallvik S.E.
        • Hildebran C.
        • Beran T.
        • Millet L.M.
        • Marino M.
        Leading a horse to water: Facilitating registration and use of a prescription drug monitoring program.
        Clin J Pain. 2015; 31: 782-787
        • Dormuth C.R.
        • Miller T.A.
        • Huang A.
        • Mamdani M.M.
        • Juurlink D.N.
        Effect of a centralized prescription network on inappropriate prescriptions for opioid analgesics and benzodiazepines.
        Can Med Assoc J. 2012; 184: E852-E856
        • Dowell D.
        • Haegerich T.M.
        • Chou R.
        CDC guideline for prescribing opioids for chronic pain—United States, 2016.
        JAMA. 2016; 315: 1624-1645
        • Fay M.P.
        Two-sided exact tests and matching confidence intervals for discrete data.
        R Journal. 2010; 2: 53-58
        • Finley E.P.
        • Garcia A.
        • Rosen K.
        • McGeary D.
        • Pugh M.J.
        • Potter J.S.
        Evaluating the impact of prescription drug monitoring program implementation: a scoping review.
        BMC Health Serv Res. 2017; 17: 420
        • Gugelmann H.M.
        • Perrone J.
        Can prescription drug monitoring programs help limit opioid abuse?.
        JAMA. 2011; 306: 2258-2259
        • Gwira Baumblatt J.A.
        • Wiedeman C.
        • Dunn J.R.
        • Schaffner W.
        • Paulozzi L.J.
        • Jones T.F.
        High-risk use by patients prescribed opioids for pain and its role in overdose deaths.
        JAMA Intern Med. 2014; 174: 796-801
        • Hartung D.M.
        • Kim H.
        • Ahmed S.M.
        • Middleton L.
        • Keast S.
        • Deyo R.A.
        • Zhang K.
        • McConnell K.J.
        Effect of a high dosage opioid prior authorization policy on prescription opioid use, misuse, and overdose outcomes.
        Subst Abus. 2017; (Oct 10; Epub ahead of print)
        • Hildebran C.
        • Cohen D.J.
        • Irvine J.M.
        • Foley C.
        • O'Kane N.
        • Beran T.
        • Deyo R.A.
        How clinicians use prescription drug monitoring programs: A qualitative inquiry.
        Pain Med. 2014; 15: 1179-1186
        • Hildebran C.
        • Leichtling G.
        • Irvine J.M.
        • Cohen D.J.
        • Hallvik S.E.
        • Deyo R.A.
        Clinical styles and practice policies: Influence on communication with patients regarding worrisome prescription drug monitoring program data.
        Pain Med. 2016; 17: 2061-2066
        • Irvine J.M.
        • Hallvik S.E.
        • Hildebran C.
        • Marino M.
        • Beran T.
        • Deyo R.A.
        Who uses a prescription drug monitoring program and how? Insights from a statewide survey of Oregon clinicians.
        J Pain. 2014; 15: 747-755
        • Kennedy-Hendricks A.
        • Richey M.
        • McGinty E.E.
        • Stuart E.A.
        • Barry C.L.
        • Webster D.W.
        Opioid overdose deaths and Florida's crackdown on pill mills.
        Am J Public Health. 2016; 106: 291-297
        • Leichtling G.J.
        • Irvine J.M.
        • Hildebran C.
        • Cohen D.J.
        • Hallvik S.E.
        • Deyo R.A.
        Clinicians' use of prescription drug monitoring programs in clinical practice and decision-making.
        Pain Med. 2017; 18: 1063-1069
        • Meara E.
        • Horwitz J.R.
        • Powell W.
        • McClelland L.
        • Zhou W.
        • O'Malley J.
        • Morden N.E.
        State legal restrictions and prescription-opioid use among disabled adults.
        N Engl J Med. 2016; 375: 44-53
        • Nam Y.H.
        • Shea D.G.
        • Shi Y.
        • Moran J.R.
        State prescription drug monitoring programs and fatal drug overdoses.
        Am J Manag Care. 2017; 23: 297-303
        • Okie S.
        A flood of opioids, a rising tide of deaths.
        N Engl J Med. 2010; 363: 1981-1985
        • O'Kane N.
        • Hallvik S.E.
        • Marino M.
        • Van Otterloo J.
        • Hildebran C.
        • Leichtling G.
        • Deyo R.A.
        Preparing a prescription drug monitoring program data set for research purposes.
        Pharmacoepidemiol Drug Saf. 2016; 25: 993-997
        • Oregon Health Authority, Center for Prevention & Health Promotion, Injury & Violence Prevention Section
        Drug Overdose Deaths, Hospitalizations, Abuse & Dependency Among Oregonians.
        (Available at:)
        • Pardo B.
        Do more robust prescription drug monitoring programs reduce prescription opioid overdose?.
        Addiction. 2016; 112: 1773-1783
        • Patrick S.W.
        • Fry C.E.
        • Jones T.F.
        • Buntin M.B.
        Implementation of prescription drug monitoring programs associated with reductions in opioid-related death rates.
        Health Aff (Millwood). 2016; 35: 1324-1332
        • Paulozzi L.J.
        • Jones C.M.
        • Mack K.A.
        • Rudd R.A.
        Vital signs: Overdoses of prescription opioid pain relievers, United States, 1999–2008.
        MMWR Morb Mortal Wkly Rep. 2011; 60: 1487-1492
        • Paulozzi L.J.
        • Kilbourne E.M.
        • Desai H.A.
        Prescription drug monitoring programs and death rates from drug overdose.
        Pain Med. 2011; 12: 747-754
        • Paulozzi L.J.
        • Kilbourne E.M.
        • Shah N.G.
        • Nolte K.B.
        • Desai H.A.
        • Landen M.G.
        • Harvey W.
        • Loring L.D.
        A history of being prescribed controlled substances and risk of drug overdose death.
        Pain Med. 2012; 13: 87-95
        • Perrone J.
        • DeRoos F.J.
        • Nelson L.S.
        Prescribing practices, knowledge, and use of prescription drug monitoring programs (PDMP) by a national sample of medical toxicologists, 2012.
        J Med Toxicol. 2012; 8: 341-352
        • Rudd R.A.
        • Aleshire N.
        • Zibbell J.E.
        • Gladden R.M.
        Increases in drug and opioid overdose deaths—United States, 2000–2014.
        MMWR Morb Mortal Wkly Rep. 2016; 64: 1378-1382
        • Rutkow L.
        • Turner L.
        • Lucas E.
        • Hwang C.
        • Alexander G.C.
        Most primary care physicians are aware of prescription drug monitoring programs, but many find the data difficult to access.
        Health Aff (Millwood). 2015; 34: 484-492
        • Young H.W.
        • Tyndall J.A.
        • Cottler L.B.
        The current utilization and perceptions of prescription drug monitoring programs among emergency medicine providers in Florida.
        Int J Emerg Med. 2017; 10: 16